COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Determine the Effect of a High-Fat Meal on the Rate and Extent of E2006 Absorption in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02089412
Recruitment Status : Completed
First Posted : March 17, 2014
Last Update Posted : November 3, 2015
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This is an open-label, single-dose, randomized crossover study of single oral 10-mg tablet doses administered either after an overnight fast or in combination with a standard high-fat meal in healthy subjects.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: E2006 Phase 1

Detailed Description:
The study will have 2 phases: Prerandomization and Randomization. The Prerandomization Phase will consist of 2 periods: Screening and Baseline (Baseline Period 1), during which each subject�s study eligibility will be determined and baseline assessments will be conducted. During this phase, each eligible subject will be randomized to 1 of 2 treatment sequences to receive single oral doses of E2006 10 mg under fasted and fed conditions. The Randomization Phase will consist of 3 periods: administration of the first randomized dose (Treatment Period 1), baseline for the second randomized dose (Baseline Period 2), and administration of the second randomized dose (Treatment Period 2).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 59 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : February 2014
Actual Primary Completion Date : May 2014
Actual Study Completion Date : June 2014

Arm Intervention/treatment
Experimental: E2006: fed conditions
E2006 10-mg will be administered as a single dose under fed treatment conditions.
Drug: E2006
Experimental: E2006: fasted conditions
E2006 10-mg will be administered as a single dose under fasted treatment conditions.
Drug: E2006

Primary Outcome Measures :
  1. Pharmacokinetics of E2006: AUC(t-0) [ Time Frame: Up to Day 15 (336 hours) ]
  2. Pharmacokinetics of E2006: AUC(t-inf) [ Time Frame: Up to Day 15 (336 hours) ]
  3. Pharmacokinetics of E2006: Maximum Concentration (Cmax) [ Time Frame: Up to Day 15 (336 hours) ]
  4. Pharmacokinetics of E2006: time attain to Cmax (tmax) [ Time Frame: Up to Day 15 (336 hours) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  1. Healthy males or females, ages 18 to 55 years
  2. Body mass index greater than 18 and less than or equal to 32 kg/m2 at Screening
  3. All females must be of nonchildbearing potential, defined as postmenopausal women (defined as at least 12 months consecutive amenorrhea, in the appropriate age group and without other known or suspected cause) or subjects who have been sterilized surgically or who are otherwise proven sterile (eg, bilateral tubal ligation with surgery at least 6 months prior to dosing, hysterectomy, or bilateral oophorectomy with surgery at least 2 months prior to dosing). In addition, females must have a negative serum B-human chorionic gonadotropin test result at Screening.
  4. Males who are not abstinent or have undergone a successful vasectomy, who are partners of women of childbearing potential must use, or their partners must use a highly effective method of contraception (eg, condom plus spermicide, condom plus diaphragm with spermicide, intrauterine device starting at least 1 menstrual cycle prior to starting study drug and throughout the entire study period and for 30 days [longer if appropriate] after the last dose of study drug)
  5. Are willing and able to comply with all aspects of the protocol
  6. Provide written informed consent

Exclusion Criteria

  1. Any subject that has a known history of malaria or has traveled to a country with known malarial risk (ie, is designated as "high" or "moderate" risk country according to the list available at within the last year
  2. Subjects with a history of bowel resection, any malabsorptive disorder, severe gastroparesis, or any gastrointestinal procedure for the purpose of weight loss (including Lapband(TM)), which would slow gastric emptying and potentially affect PK profiles of E2006
  3. Subjects with a known history of clinically significant drug or food allergies or a known allergy or hypersensitivity to capsule or tablet ingredients
  4. Subjects who experienced a weight loss or gain of greater than 10% between Screening and prior to dosing
  5. Subjects who had a clinically significant illness that required medical treatment within 8 weeks or a clinically significant infection within 4 weeks of dosing
  6. Subjects with any clinically abnormal symptom or organ impairment found in medical history, symptoms or signs, vital sign measurements, electrocardiogram (ECG) findings, or laboratory test results that require medical treatment found in medical history or at screening and baseline
  7. Subjects known to be positive for human immunodeficiency virus, or subjects who have positive hepatitis B or hepatitis C screening test results
  8. Subjects who have a history of drug or alcohol dependency or abuse (as defined by The Diagnostic and Statistical Manual of Mental Disorders V criteria) within approximately 2 years prior to Screening, or who have a positive urine drug test result at Screening or Baseline
  9. Subjects who received blood products within 4 weeks, donated blood within 8 weeks, or donated plasma within 1 week of dosing
  10. Subjects who used hormonal replacement therapy within 3 months prior to dosing
  11. Subjects who used any drugs, over-the-counter medications, nutritional supplements (eg, products containing St. John's wort), excessive doses of vitamins (in the opinion of the principal investigator), herbal preparations, or foods or beverages known to modulate cytochrome P450 ([CYP] eg, CYP3A4) or transporters within 4 weeks prior to dosing, or who are unwilling to abstain from using these during the study
  12. Subjects who engaged in intense physical activity within 1 week prior to Baseline (eg, weight training)
  13. Subjects who smoke or have used tobacco- or nicotine-containing products within 3 months prior to dosing
  14. Subjects who habitually consume more than 400-mg caffeine per day
  15. Subjects who participated (received investigational product) in another clinical trial less than 1 month (or 5 elimination half-lives of the investigational product) prior to dosing or who are currently enrolled in another clinical trial
  16. Subjects with a disease that may influence the outcome of the study, such as psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or subjects who have a congenital abnormality in metabolism, or subjects who have any condition that would make him or her, in the opinion of the investigator, unsuitable for the study or who, in the opinion of the investigator, are not likely to complete the study for any reason

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02089412

Layout table for location information
United States, Texas
PPD Development LLC
Austin, Texas, United States, 78744
Sponsors and Collaborators
Eisai Inc.
Layout table for additonal information
Responsible Party: Eisai Inc. Identifier: NCT02089412    
Other Study ID Numbers: E2006-A001-008
First Posted: March 17, 2014    Key Record Dates
Last Update Posted: November 3, 2015
Last Verified: November 2015
Keywords provided by Eisai Inc.:
Healthy Subjects
High-Fat Meal